The ISGIDAR NEWSLETTER
VOL. 24, NO. 2 October, 1998

CORRESPONDENCE

| ABOUT ISGIDAR:  
| (President of ISGIDAR) | ABOUT ISGIDAR NEWSLETTER:  
| (Secretary of ISGIDAR) |
|------------------------|--------------------------|
| Patrick M. Beardsley, Ph.D. 
| Medical College of Virginia  
| Dept. of Pharmacology and Toxicology  
| P.O. Box 980613  
| 410 North 12th St.  
| Smith Bldg. #756A  
| Richmond, VA 23298-0613  
| tel: (804) 828-5185  
| email: pbeardsl@hsc.vcu.edu |
| James P. Zacny, Ph.D.  
| Dept. of Anesthesia & Critical Care  
| MC4028  
| The University of Chicago  
| 5841 S. Maryland Avenue  
| Chicago, IL 60637  
| tel: (773) 702-9920  
| email: zacn@midway.uchicago.edu |

INDEX

NOMINATIONS FOR NEW MEMBERS
RECENT PUBLICATIONS FROM OUR MEMBERS
POSITIONS AVAILABLE

1998 Meeting of the International Study Group 
Investigating Drugs as Reinforcers

June 13, 1998 
Scottsdale, Arizona

9:00 HAS OUR OBSESSION WITH ORDER AND PREDICTABILITY MADE US IRRELEVANT? Schuster CR (Invited Speaker)
9:05 EFFECT OF ABT-431, A SELECTIVE D1 AGONIST, ON SMOKED COCAINE SELF-ADMINISTRATION IN HUMANS. Haney M, Collins ED, Foltin RW, Fischman MW
9:30 A CHOICE PROCEDURE FOR STUDYING ORAL AMPHETAMINE SELF-ADMINISTRATION BY BABOONS. Foltin RW
9:55 EFFECTS OF REPRODUCTIVE CYCLE ON OPERANT RESPONDING FOR COCAINE AND SUCROSE. Hecht GS, Spear LP
10:20 REINFORCEMENT FREQUENCY AS A DETERMINANT OF DRUG CHOICE: DOES DRUG CLASS MATTER? Andersen KG, Woolverton WL
10:45 FIRING PATTERNS OF SINGLE NUCLEUS ACCUMBENS NEURONS IN RATS INTRAVENOUSLY SELF-ADMINISTERING COCAINE. Peoples LL, Uziwiaj AJ, Gee F, West MO
11:10 EFFECTS OF SOCIAL STRESS AND THE AVAILABILITY OF AN ALTERNATIVE, NONDRUG REINFORCER ON ACQUISITION OF COCAINE SELF-ADMINISTRATION IN GROUP HOUSED
Cynomolgus Monkeys. Morgan D, Grant K, Kaplan J, Mach R, Nader M
Naltrexone Pretreatment Decreases the Reinforcing Efficacy of Ethanol and Saccharin but Not PCP or Food under a Concurrent Progressive-Ratio Schedule in Monkeys. Rodefer J. (Student Travel Awardee)

11:35 Lunch

12:00 IS Food-Maintained Behavior the Appropriate Control for Determining Selectivity of Pharmacotherapy? Carroll ME, Campbell UC

1:00 Reinforcing Effects of Caffeine, Ephedrine and Their Binary Combination in Rats. Briscoe RJ

1:15 Individual Differences in Biphasic Effects of Ethanol. Holdstock L, de Wit H

1:40 Measures of the Oral Reinforcing Effects of Drugs in Rhesus Monkeys. Woods JH, Vivian J

2:05 E pluribus unum or e unum pluribus? Reinforcement and Its Measurement. Bickel WK, Madden G, Jacobs E


3:00 Measurement of Relative Reinforcing Efficacy of Drugs of Abuse Using the Metric of Response Output. Woolverton WL

3:30 Measuring the Reinforcing Efficacy of Drugs. Invited Commentary. Killeen PR

3:55 Business Meeting

Business Meeting Minutes

The Treasurer, Marilyn Carroll, reported that the income generated by this year's meeting was $2935, and the expenses of the meeting amounted to $3929 [Princess bill for room, breakfast, drinks, etc.: $3260], which left a net loss of $994. The luncheon at this year's meeting cost participants $15. We lost $96 on the luncheon because there were some tickets left unsold. ISGIDAR currently has $1517.85 in its treasury. Marilyn also stated that the Princess charged us double what they did two years ago, which makes the Princess very expensive to hold our meetings at.

Jim Woods suggested that future ISGIDAR meetings have part of the meeting devoted to a central topic. Other members agreed and commented that this year's meeting which had part of it devoted to the concept and measurement of the reinforcing efficacy of drugs went particularly well. ISGIDAR's president suggested that potential topics for next year's meeting be e-mailed to him (pbeardsl@hsc.vcu.edu) for consideration for next year's meeting.

There was some discussion devoted to length of talks, with one suggestion to shorten talks and another suggestion to lengthen talks. The consensus was that people could be asked by the President when they submit a talk how many minutes they need for the presentation with a minimum UL>

Review:
Each manuscript will be independently reviewed by the ISGIDAR officers for originality, scientific contribution, methodology and clarity. Blind review is possible upon request. Reviewers will not participate in the review of papers from their own institution.

Submit manuscripts to:
Patrick M. Beardsley, Ph.D.
Medical College of Virginia
Dept. of Pharmacology and Toxicology
P.O. Box 980613
Richmond, VA 23298-0613

Luncheon Information

Our President (not Clinton but Beardsley) has been in discussion with the Scottsdale Princess via the Sailair folks trying to negotiate an affordable luncheon during the ISGIDAR meeting. Previously, those choosing to attend the ISGIDAR luncheon paid about $15. This year the Scottsdale Princess initially quoted a price of $36 a person for a basic buffet lunch which is in excess of most of our per diems. Negotiations are ongoing and there is some hope that a satisfying lunch can still be provided at the Princess for $15. Regardless of the outcome of these negotiations, we will have an ISGIDAR luncheon. If the Princess remains prohibitively expensive, off-site restaurants have already been identified as potential luncheon sites. Luncheon information, including costs and content, along with sign-up sheets will be available at the ISGIDAR registration desk. ISGIDAR's luncheon has always been a great chance to meet colleagues, discuss science (baseball, music, politics and other reinforcers or punishers) and to find out who is looking for students or look for college of Virginia - VCU balster@hsc.vcu.edu

Stephen J. Heishman, Ph.D. 5500 Nathan Shock Drive
Clinical Pharmacology Baltimore, MD 21224
NIDA Addiction Research Center sheish@intra.nida.nih.gov


Harriet de Wit, Ph.D. 5841 S. Maryland Avenue
Department of Psychiatry Chicago IL 60637, USA
The University of Chicago hdew@midway.uchicago.edu


Leslie Amass, Ph.D. 1741 Vine Street
Vine Street Center, Department of Psychiatry Denver, CO 80206
• Bickel, W.K., Amass, L., Crean, J.P., and Badger, G.J. Chronic buprenorphine dosing every 72 hours in opioid-dependent humans: Agonist and antagonist effects. Psychopharmacology, in press.

R.A. Meisch, M.D. 1300 Moursund Blvd.
Psychiatry / UTH-HSC Houston, TX 77030-3497
rmeisch@msi13.msi.uth.tmc.edu


Anthony Liguori, Ph.D. Medical Center Blvd.
Dept. of Physiology & Pharmacology Winston-Salem, NC 27157-1083
The Bowman Gray School of Medicine, Wake Forest University aliguori@wfubmc.edu


POSITIONS AVAILABLE

POST-DOCTORAL POSITION IN HUMAN PSYCHOPHARMACOLOGY available in the Department of Psychiatry at The University of Chicago. Laboratory-based studies investigate risk factors for drug use, as well as direct effects of drugs on mood, cognition and behavior. Current projects focus on impulsivity and risk-taking, drug-hormone interactions, and individual differences. Send cv and names of three references to H. de Wit, Ph.D., Department of Psychiatry, The University of Chicago, MC3077, 5841 S. Maryland Avenue, Chicago IL 60637 or email hdew@midway.uchicago.edu
RESEARCH ASSOCIATE, Department of Psychiatry, University of Mississippi Medical Center. Develop, implement and publish research relating to the behavioral neuropharmacology of abused drugs, particularly drug self-administration and drug discrimination in non-human primates. The relationship between in vitro or in vivo neuropharmacology and behavioral effects is of central interest. Ph.D. in pharmacology or neuroscience required. Salary commensurate with experience. Send c.v., statement of research goals, and names of three references to: William L. Woolverton, Ph.D., Department of Psychiatry and Human Behavior, The University of Mississippi Medical Center, 2500 N. State Street, Jackson, MS, 39216. EOE, M/F/D/V.

POSTDOCTORAL FELLOW POSITION in behavioral pharmacology to study the discriminative stimulus, reinforcing, antinociceptive, ventilatory and other effects of benzodiazepines, opioids and psychomotor stimulants in normal and dependent subjects. Applicants should have a Ph.D. and background in pharmacology, psychology, or neuroscience. Send curriculum vitae, description of research interests, reprints and the names of three references to C.P. France, Ph.D., Department of Pharmacology, LSU Medical Center, 1901 Perdido Street, New Orleans, LA 70112-1393 (cfranc@lsumc.edu). AA/ADA/EOE.

POSTDOCTORAL POSITION IN NICOTINE/SMOKING RESEARCH. A post-doctoral position is available in nicotine/smoking research with Dr. Kenneth A. Perkins at the University of Pittsburgh. This research centers on the behavioral pharmacology of nicotine in humans. NIDA-supported projects include nicotine discrimination and the relationship of nicotine tolerance to tobacco dependence and self-administration. Other studies examine sex differences in nicotine effects and interactions between nicotine and other drugs. Collaboration with other faculty conducting similar research with non-human animals is possible. Applicants also interested in clinical research may become involved in smoking cessation studies. Interested candidates should send a C.V. and letter of interest to: Kenneth A. Perkins Ph.D., Professor of Psychiatry, WPIC, University of Pittsburgh School of Medicine, 3811 O'Hara Street, Pittsburgh PA 15213 phone: (412) 624-1716; fax: (412) 624-6018

POSTDOCTORAL RESEARCH IN DRUG ABUSE. The National Institute on Drug Abuse (NIDA) has a postdoctoral position available in Clinical Pharmacology. The research program involves clinical studies on 1) attentional deficits and tobacco craving observed during nicotine withdrawal and 2) cognitive and psychomotor effects of marijuana and other drugs. The candidate must have a Ph.D., and a background in cognitive or experimental psychology or behavioral pharmacology is highly desirable. Candidates must be U.S. citizens or permanent residents. Salary is commensurate with postdoctoral experience. Applicants must submit a curriculum
vitae and names of three references no later than 30 November 1998 to: Stephen J. Heishman, Ph.D., Clinical Pharmacology, NIDA/IRP, 5500 Nathan Shock Drive, Baltimore, MD 21224. Questions about the position may be addressed to Dr. Heishman (410-550-1547). NIDA is an equal opportunity employer and encourages applications from women and minorities.

SUBSTANCE ABUSE BEHAVIORAL PHARMACOLOGY AND BEHAVIOR THERAPY RESEARCH AT JOHNS HOPKINS. Postdoctoral human research fellowships in a stimulating and productive environment with excellent clinical and research resources. Two types, fellows may pursue either or both:

- Human Laboratory Studies related to the clinical and behavioral pharmacology of abused drugs (abuse liability testing, drug discrimination, drug self-administration, physical dependence) and anti-drug-abuse medications development. Opioids, cocaine, anxiolytics, caffeine, nicotine.
- Clinical Trials of Substance Abuse Treatments -- controlled evaluations of pharmacotherapies and behavior therapies (esp. incentive-based therapies), and their interactions. Opioid, cocaine, nicotine, mixed/other dependence.

**Goal:** Preparation for careers as independent investigators.
**Duration:** Typically 2 years.
**Eligibility:** U.S. citizens or permanent residents only. Minorities encouraged.
**Stipends:** USPHS/NIH stipend levels based on experience, $21,000-33,012.
Contact George E. Bigelow, Ph.D., Roland Griffiths, Ph.D. or Maxine L. Stitzer, Ph.D.; BPRU, Behavioral Biology Research Center; 5510 Nathan Shock Drive; Johns Hopkins Bayview Campus; Baltimore, Maryland 21224-6823. (410) 550-0035; bigelow@jhmi.edu.

POSTDOCTORAL RESEARCH IN LABORATORY ANIMAL BEHAVIORAL PHARMACOLOGY, MEDICAL COLLEGE OF VIRGINIA, DEPARTMENT OF PHARMACOLOGY & TOXICOLOGY. Postdoctoral research positions are available in laboratory animal behavioral pharmacology. Positions are possible utilizing almost any behavioral pharmacological approach to the study of the behavioral and/or neurochemical mechanisms mediating the activity of the drugs of abuse. Ongoing studies utilize mice, rats, squirrel monkeys, and rhesus monkeys in discrimination, self-administration, and other operant and respondent procedures involving all routes of systemic and central drug administration. Of particular current emphasis are studies involving the:

- pharmacology of dopamine D3 receptor ligands
- pharmacology of excitatory amino acid agents
- development of medications for the treatment of drug-dependency disorders
• pharmacology of behaviorally-active inhalation agents
• development of drug i.v. rat self-administration relapse procedures

Many opportunities exist for collaborating with other researchers in the department who have major research foci upon the stimulants and hallucinogens, cannabinoids, nicotine, and the opiates. Send vita, letter of interest, and names and telephone numbers of 2 references to: Patrick M. Beardsley, Ph.D. or Robert L. Balster, Ph.D.; Medical College of Virginia, Department of Pharmacology, P.O. Box 980613, Richmond, VA 23298-0613. (804) 828-5185.